SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)
Clin. transl. oncol. (Print)
; 21(1): 3-17, ene. 2019. tab, graf
Artigo
em Inglês
| IBECS
| ID: ibc-183340
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
Non-small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. The last few years have seen the development of a new staging system, diagnostic procedures such as liquid biopsy, treatments like immunotherapy, as well as deeper molecular knowledge; so, more options can be offered to patients with driver mutations. Groups with specific treatments account for around 25% and demonstrate significant increases in overall survival, and in some subgroups, it is important to evaluate each treatment alternative in accordance with scientific evidence, and even more so with immunotherapy. New treatments similarly mean that we must reconsider what should be done in oligometastatic disease where local treatment attains greater value
RESUMEN
No disponible
Texto completo:
Disponível
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Carcinoma Pulmonar de Células não Pequenas
/
Neoplasias Pulmonares
/
Estadiamento de Neoplasias
Limite:
Humanos
Idioma:
Inglês
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2019
Tipo de documento:
Artigo
Instituição/País de afiliação:
Complexo Hospitalario Universitario A Coruña/Spain
/
Hospital Clínico Universitario de Valencia/Spain
/
Hospital General Universitario de Elche/Spain
/
Hospital Germans Trias i Pujol/Spain
/
Hospital Universitari i Politècnic La Fe/Spain
/
Hospital Universitario Virgen de la Victoria/Spain
/
Hospital de la Santa Creu i Sant Pau/Spain
/
Parc Taulí Hospital Universitari/Spain
/
Universidad Autónoma de Madrid/Spain
/
Universitat de Barcelona/Spain